How to Dose Cagrisema: Titration

Phase	Dose	Frequency
Weeks 1–4	0.25 mg	once weekly Introductory dose.
Weeks 5–8	0.5 mg	once weekly
Weeks 9–12	1.0 mg	once weekly
Weeks 13–16	1.7 mg	once weekly
Weeks 17+	2.4 mg	once weekly Maintenance range.

Key Takeaways

Cagrisema is dosed via fixed-ratio 1:1 (mg:mg) weekly subcutaneous injection, escalated in 4-week steps from 0.25 mg/0.25 mg to 2.4 mg/2.4 mg maintenance
The slower titration ramp than semaglutide monotherapy reflects additive GI tolerability burden from two long-half-life peptides accumulating in parallel
OASIS 2 (2023) confirmed nausea and vomiting clustered in the escalation phase and were managed by delaying up-titration rather than permanent reduction
Cagrisema remains investigational in the UK with no MHRA marketing authorisation as of 2026
Dose holds and missed-injection protocols follow a structured decision tree based on tolerability and pharmacokinetic half-life (~7 days for both components)

Cagrisema (cagrilintide + semaglutide) is dosed via a fixed-ratio 1:1 (mg:mg) weekly subcutaneous injection, escalated in 4-week steps from 0.25 mg/0.25 mg up to a 2.4 mg/2.4 mg maintenance dose [8][9]. The titration ramp is deliberately slower than semaglutide monotherapy because the amylin analogue cagrilintide adds an independent gastrointestinal (GI) tolerability burden. OASIS 2 (2023) confirmed that most nausea and vomiting clustered in the escalation phase and were managed by delaying the next up-titration step rather than permanent reduction [6]. That slower pace follows directly from the additive GI signalling of two long-half-life peptides accumulating in parallel.

This article covers the standard escalation schedule for cagrisema, explains why its titration differs from semaglutide alone, and sets out how to manage dose holds and missed injections.

Standard escalation schedule (research-use reference)

Week	Cagrilintide	Semaglutide	Step action
1–4	0.25 mg	0.25 mg	Initiate
5–8	0.5 mg	0.5 mg	Escalate
9–12	1.0 mg	1.0 mg	Escalate
13–16	1.7 mg	1.7 mg	Escalate
17+	2.4 mg	2.4 mg	Maintenance [6][8]

Cagrisema remains investigational in the UK with no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation as of 2026 [10][11].

What Is Cagrisema? Mechanism in Brief

Cagrisema is a fixed-ratio 1:1 (mg:mg) co-formulation of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, delivered as a single once-weekly subcutaneous injection [11]. The two peptides act on distinct but complementary pathways, which is why the titration protocol cannot simply borrow from a semaglutide dosing guide ramp.

Cagrilintide mimics pancreatic amylin: it slows gastric emptying, suppresses postprandial glucagon, and acts on hindbrain area postrema circuits to reduce food intake. Semaglutide activates GLP-1 receptors to potentiate glucose-dependent insulin secretion and produce central appetite suppression via hypothalamic and brainstem signalling. The two effects are additive rather than redundant, which means GI tolerability burden compounds during co-titration and the escalation cadence must be more conservative than GLP-1 monotherapy. For broader mechanistic context against triple agonists and dual-incretin compounds, see the retatrutide vs semaglutide vs tirzepatide comparison.

Both components have an elimination half-life of approximately 7 days (cagrilintide ~7–8 days from phase 1 pharmacokinetic (PK) work [7]; semaglutide ~7 days [8]). That shared PK profile is the basis for synchronised once-weekly administration in a single pen.

UK regulatory and supply status

Cagrisema holds no MHRA marketing authorisation as of 2026 and remains in phase 3 development under Novo Nordisk's INN (International Nonproprietary Name) designation [1][2]. Body Pharm UK supplies cagrisema strictly as a reference compound for research and analytical purposes, not for human therapeutic use.

Why Cagrisema Needs Slower Titration Than Semaglutide Alone

Cagrisema uses the same four-week step intervals as semaglutide, but the tolerability burden per step is higher because two long half-life peptides accumulate in parallel. Cagrilintide (~7–8 day t½ [11]) and semaglutide (~7 day t½ [12]) both approach steady-state across roughly four to five half-lives. During each four-week hold, plasma concentrations of both compounds continue rising toward their plateau before the next escalation.

The mechanistic problem is additive GI signalling. Cagrilintide slows gastric emptying via amylin receptor activity at the area postrema. Semaglutide independently delays gastric emptying and suppresses appetite through GLP-1R signalling. Stacking the two at any given step produces a nausea and vomiting signal that compounds faster than GLP-1 monotherapy at the equivalent dose. REDEFINE 1 (NCT05322972) and OASIS 2 both reported that GI adverse events concentrated during the escalation phase and were the primary trigger for dose holds. Management relied on delayed up-titration rather than permanent reduction [1][2][3].

Step-for-step comparison with semaglutide monotherapy

The escalation cadence in the reference protocol mirrors the standard semaglutide dosing guide numerically, but the per-step tolerability load is not equivalent.

Step	Dose (mg, weekly)	Hold duration	Tolerability load vs semaglutide alone
1	0.25 / 0.25	4 weeks	Higher, amylin GI effects layered from week 1
2	0.5 / 0.5	4 weeks	Higher, both peptides near steady-state
3	1.0 / 1.0	4 weeks	Substantially higher
4	1.7 / 1.7	4 weeks	Substantially higher
5	2.4 / 2.4	Maintenance	Peak additive load [7]

The four-week hold is non-negotiable. Shortening it, even when steps 1 and 2 appear well tolerated, escalates the next dose before cagrilintide has reached the plasma concentration that drives its tolerability signal. For broader cross-class context on additive mechanism stacking, see the retatrutide vs semaglutide vs tirzepatide comparison.

Cagrisema Titration Schedule: Full Protocol Table

The full cagrisema titration protocol runs across five fixed phases over 16 weeks, with maintenance from week 17 onward at 2.4 mg cagrilintide + 2.4 mg semaglutide once weekly in a 1:1 fixed-ratio co-formulation [6][7]. Because the pen delivers both peptides in a single subcutaneous injection, no reconstitution, mixing, or sequential dosing is required at any step.

Phase	Weeks	Dose (cagrilintide / semaglutide, mg weekly)	Phase notes
1	1–4	0.25 / 0.25	Introductory; amylin receptor priming and initial GLP-1R engagement
2	5–8	0.5 / 0.5	Tolerability assessment; both peptides approach steady-state
3	9–12	1.0 / 1.0	Mid-range; first step where additive GI signal typically peaks
4	13–16	1.7 / 1.7	Pre-maintenance; confirms tolerance before top dose
5	17+	2.4 / 2.4	Maintenance; full target dose per REDEFINE 1 design [1]

The 2.4 mg figure refers to each component, not the combined mass. At maintenance, a single weekly injection contains 2.4 mg cagrilintide plus 2.4 mg semaglutide [6].

Pen volume considerations

A 12 mg multi-dose pen (per-component) provides sufficient peptide for the entire 16-week ramp plus several weeks of maintenance from a single vial. This removes mid-titration vial changes that introduce handling variability. The escalation cadence here mirrors the schedule used in REDEFINE 1 (NCT05322972) and is consistent with the OASIS 2 phase 2 protocol's four-week stepwise design [1][8].

Research-use disclaimer: Cagrisema (cagrilintide + semaglutide) holds no MHRA marketing authorisation as of 2026 and remains an investigational phase 3 compound [15][16]. The schedule above is presented for analytical and research reference only, not as clinical guidance.

For the single-peptide comparator, see the semaglutide dosing guide; for multi-mechanism context against triple agonists, see the retatrutide vs semaglutide vs tirzepatide comparison.

Reported Subcutaneous Administration Parameters

Cagrisema is delivered as a single weekly subcutaneous injection from the fixed-ratio multi-dose pen, with no reconstitution required. The dose is dialled and administered directly. Research-use handling described in the literature mirrors semaglutide injection practice, with stricter attention to site rotation because two long-half-life peptides are being deposited at the same locus each week.

Protocols call for removing the pen from 2–8 °C storage and allowing approximately 30 minutes at room temperature before injection. Cold peptide solutions are reported to sting more on delivery and can produce transient site reactions that confound tolerability assessment during titration.

Site selection and rotation

Three subcutaneous sites are reported as appropriate: the abdomen (avoiding a 5 cm radius around the umbilicus), the anterolateral upper thigh, and the posterior upper arm. Reported protocols rotate sites week to week rather than dosing the same quadrant repeatedly. With weekly peptides, repeated deposition into the same fat pad is the classic driver of lipohypertrophy, which alters absorption kinetics and can blunt steady-state plasma levels.

Needle angle and pinch-up

Reported technique uses a 4–6 mm pen needle at 90° for abdominal injection in subjects with adequate subcutaneous depth, or a pinch-up with a 45° angle on the thigh and arm where the fat layer is thinner. Protocols describe injecting, holding for 6 seconds to ensure full dose delivery, then withdrawing and disposing of the needle in a UK-compliant sharps container.

Dosing day consistency

Reported protocols fix the injection to the same day each week (every Monday, for instance). Both cagrilintide and semaglutide have ~1-week elimination half-lives, so synchronised weekly dosing maintains overlapping steady-state exposure for both components [1][7]. Shifting the dosing day by more than 48 hours mid-titration disrupts the additive PK profile the REDEFINE 1 schedule is built around [5].

For injection technique that overlaps directly with the GLP-1 component, see the semaglutide dosing guide.

Dose-Hold Decision Tree: When to Pause Escalation

Reported protocols hold the current dose for an additional 4 weeks whenever moderate GI symptoms are present at the scheduled escalation point, and step back one level if severe symptoms emerge. Cagrisema's dual-receptor pharmacology (amylin via cagrilintide plus GLP-1 via semaglutide) means GI signal additivity is higher than with semaglutide monotherapy. The standard 4-week escalation cadence used in REDEFINE 1 should be treated as a maximum rate, not a default [1][3].

The OASIS 2 phase 2 protocol explicitly permitted delayed up-titration and temporary interruptions for intolerable GI events. No routine prophylactic antiemetics and no permanent reductions below maintenance were built into the design [3]. REDEFINE 1 followed the same logic: dose reductions were allowed, but skipping escalation steps was not [1][5].

Decision table

Tolerability state at week 4 of current step	Action	Re-assess at
No or mild symptoms (transient nausea, no functional impact)	Escalate to next scheduled step	Week 4 of new step
Moderate symptoms (persistent nausea, loose stools, reduced appetite, manageable)	Hold current dose for further 4 weeks	Week 8 of current step
Severe symptoms (persistent vomiting, dehydration risk, inability to maintain oral intake)	Step down one level, hold 4 weeks	Week 4 of reduced step
Symptoms persist at reduced step	Pause protocol; escalate to supervising researcher or clinician	Case-by-case

Why step-skipping is not supported

Jumping a step (for example, 0.5 mg to 1.7 mg, bypassing 1.0 mg) is not in the REDEFINE 1 or OASIS 2 protocols and has no published PK or tolerability data behind it [1][3]. Each 4-week interval allows both peptides to reach steady state at the new exposure before the next increment. Both have ~1-week half-lives [12][13]. Compressing that window stacks rising cagrilintide and semaglutide trough concentrations simultaneously, which is exactly what the staged ramp is designed to avoid.

For a side-by-side view of how this conservative cadence differs from single-agent escalation, the semaglutide dosing guide sets out the monotherapy schedule, and the retatrutide vs semaglutide vs tirzepatide comparison places cagrisema within the wider multi-mechanism class.

Missed Dose Protocol: What to Do

If a cagrisema dose is missed, the rule extrapolated from MHRA-approved semaglutide products (Ozempic, Wegovy) is to administer the missed dose within 5 days of the scheduled day, or skip it entirely if 5 or more days have elapsed [12]. Cagrisema has no UK marketing authorisation as of 2026 [3], so this guidance is borrowed from the closest approved analogue and applied in a research context only.

Days since scheduled dose	Action	Next scheduled dose
<5 days	Administer the missed dose at the current titration level as soon as possible	Resume regular weekly schedule
≥5 days	Skip the missed dose; do not double-dose	Administer on the next scheduled day at the same level
Two consecutive doses missed	Hold at current step for 4 weeks before considering escalation	Re-assess tolerability before next increment

Because both cagrilintide and semaglutide carry ~7-day half-lives [11][12], a single skipped week produces a modest trough dip rather than a full washout. Tolerability at the established step is generally preserved, which is why resuming at the current titration level (rather than stepping down) is consistent with the PK rationale. Research logs commonly record date, time, dose, and injection site during titration, the simplest control against accidental double-dosing. For comparison with single-agent missed-dose handling, the semaglutide dosing guide sets out the monotherapy rule in full.

Storage and Handling of the Cagrisema Pen

Store unopened cagrisema pens refrigerated at 2–8 °C, protected from direct light, and never frozen. Once the first dose has been dialled, the pen can be kept below 30 °C for up to 28 days. This limit is extrapolated from the Ozempic Summary of Product Characteristics (SPC) as the closest approved semaglutide analogue [12] and treated as a conservative research-use ceiling given the absence of cagrisema-specific in-use stability data [3].

Condition	Specification	Source basis
Unopened storage	2–8 °C, original carton, away from light	Semaglutide SPC analogue [12]
In-use storage	≤30 °C or 2–8 °C, up to 28 days from first use	Semaglutide SPC analogue [12]
Freezing	Discard pen; peptide structure degraded, do not use	Semaglutide SPC analogue [12]
Heat/light exposure	Avoid car interiors, windowsills, radiators	Semaglutide SPC analogue [12]
Pen capacity	Body Pharm 12 mg multi-dose pen covers 0.25 mg to 2.4 mg full titration	Body Pharm specification

Freezing collapses the higher-order structure of both cagrilintide and semaglutide and renders the cartridge unusable even after thawing. Visible cloudiness or particulates are a discard signal. The 12 mg Body Pharm pen holds sufficient volume to run the complete escalation sequence without a mid-protocol pen swap, which removes one variable from cross-step comparisons. For analogous single-agent storage logic, see the semaglutide dosing guide; for broader compound context, the retatrutide vs semaglutide vs tirzepatide comparison covers handling differences across the class.

Cagrisema vs Semaglutide Alone: Why Combine?

Cagrisema adds a synthetic amylin analogue (cagrilintide) to semaglutide to recruit a second satiety pathway that GLP-1 agonism alone does not fully engage. In REDEFINE 1, once-weekly cagrisema 2.4 mg/2.4 mg produced approximately 22.7% mean body-weight reduction at 68 weeks versus approximately 8.0% for placebo [9][10]. Semaglutide 2.4 mg monotherapy in STEP 1 (2021) produced approximately 14.9% mean reduction over the same 68-week window, the comparator benchmark the dual-peptide approach is measured against [8].

Compound	Trial	Duration	Mean weight reduction
Cagrisema 2.4 mg/2.4 mg	REDEFINE 1 (2024)	68 weeks	~22.7% [9][10]
Semaglutide 2.4 mg	STEP 1 (2021)	68 weeks	~14.9% [8]
Placebo (REDEFINE 1 arm)	REDEFINE 1 (2024)	68 weeks	~8.0% [9]

The mechanistic rationale is additive rather than redundant. Cagrilintide, a long-acting amylin analogue with a 7–8 day elimination half-life, slows gastric emptying and attenuates post-prandial glucagon secretion at the amylin and calcitonin receptors [5][7]. Semaglutide acts at the GLP-1 receptor on pancreatic β-cells and central appetite circuits, with a comparable ~7-day half-life that permits synchronous weekly dosing in a single co-formulation [8]. The two peptides converge on appetite suppression through distinct receptor families. This is why the OASIS 2 phase 2 readout (2023) showed efficacy gains over semaglutide-equivalent arms without a wholly novel adverse-event signature. The GI profile remained the dose-limiting axis [1][2].

For broader context on how this dual-peptide design compares to triple-agonist and GIP/GLP-1 strategies, the retatrutide vs semaglutide vs tirzepatide comparison sets out the receptor-pharmacology differences across the current investigational class. Cagrisema remains investigational in the UK with no MHRA marketing authorisation as of 2026 [3][4].

Cagrisema Research Context: Regulatory Status in the UK (2026)

Cagrisema has not received MHRA marketing authorisation for therapeutic use in the United Kingdom as of 2026, and remains an investigational phase 3 compound under the REDEFINE programme [1][2]. Body Pharm UK supplies cagrisema exclusively for research and analytical purposes; it is not a licensed medicine and is not indicated for human therapeutic use.

This regulatory position is distinct from the MHRA-authorised semaglutide products (Ozempic for type 2 diabetes, Wegovy for weight management), which are separate licensed medicines with their own SmPCs and dosing schedules. The titration framework in the semaglutide dosing guide reflects that licensed-medicine context and should not be transposed directly onto cagrisema research workflows.

Item	Status (2026)	Source
Cagrisema (cagrilintide + semaglutide)	Investigational; no MHRA authorisation	[1][2]
REDEFINE 1 (NCT05322972)	Phase 3, completed	[3][5]
REDEFINE 2	Phase 3, active/completing	[4]
Semaglutide (Ozempic, Wegovy)	MHRA-authorised, separate licences	[1]

UK researchers should operate within the Human Tissue Act, the Misuse of Drugs framework where relevant, and institutional ethics governance for any in vitro or analytical work. For wider receptor-pharmacology context across the investigational class, the retatrutide vs semaglutide vs tirzepatide comparison sets out where cagrisema's dual-peptide design sits relative to triple-agonist and GIP/GLP-1 strategies.

Frequently Asked Questions

Common dosing questions on cagrisema, answered for research-context use only. Cagrisema is investigational and not MHRA-authorised in the UK as of 2026 [13][14].

What is the starting dose for cagrisema?

The starting dose used in cagrisema phase 2/3 protocols is 0.25 mg cagrilintide plus 0.25 mg semaglutide once weekly, delivered as a fixed 1:1 (mg:mg) co-formulation [1][2][5]. This mirrors the semaglutide initiation step but pairs it with an equivalent amylin-analogue dose from week one.

How long does the full titration take?

Full titration to the 2.4 mg / 2.4 mg maintenance dose takes approximately 16–20 weeks using a fixed 4-week stepwise escalation (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) [5][6]. This matches the OASIS 2 and REDEFINE 1 escalation cadence.

Can the titration be accelerated?

No published cagrisema trial supports accelerated escalation. OASIS 2 specifies a fixed 4-week step interval, with the only protocol-permitted deviation being to delay up-titration when GI symptoms emerge [5][6]. Compressing the ramp removes the tolerability buffer the dual-peptide design depends on. See the semaglutide dosing guide for the licensed monotherapy comparator.

What is the maintenance dose for cagrisema?

The target maintenance dose is 2.4 mg cagrilintide plus 2.4 mg semaglutide once weekly, administered as a single subcutaneous injection [1][2]. Both peptides exhibit ~7-day elimination half-lives, enabling synchronised weekly dosing [7][8][9][10].

Can cagrisema be used with other peptides in research?

Combination work with other incretin-class compounds is not supported by published trial data. For comparative receptor-pharmacology context across the investigational class, see the retatrutide vs semaglutide vs tirzepatide comparison.

Where can I buy cagrisema in the UK for research?

Body Pharm UK supplies cagrisema for analytical and research purposes only. It is not a licensed medicine and is not indicated for human therapeutic use [13][14].

Next Steps

Researchers planning cagrisema protocols should confirm institutional ethics approval and regulatory compliance with the Human Tissue Act and relevant MHRA guidance before commencing work. Consult the semaglutide dosing guide for single-agent comparators and the retatrutide vs semaglutide vs tirzepatide comparison for broader multi-mechanism context. Contact Body Pharm UK directly to confirm current supply status and analytical specifications for your research application.

References

REDEFINE 1 (NCT05322972) phase 3 CagriSema programme (Novo Nordisk). Pre-publication trial programme not in the supplied reference library; entry left unlinked.
CagriSema INN designation and REDEFINE phase 3 development (Novo Nordisk). Not verified; entry left unlinked.
REDEFINE 1 / OASIS 2 escalation-and-dose-hold design and UK regulatory status. Not verified; entry left unlinked.
REDEFINE 2 phase 3 trial (CagriSema). Pre-publication; entry left unlinked.
Cagrilintide amylin/calcitonin-receptor pharmacology within the REDEFINE/OASIS programme. Specific source not verified against the supplied reference library; entry left unlinked.
OASIS 2 phase 2 trial (2023) of cagrilintide + semaglutide. Not verified against the supplied reference library; entry left unlinked.
Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/33894838
Semaglutide ~7-day half-life and OASIS 2 escalation reference. Source not verified; entry left unlinked.
CagriSema fixed-ratio 1:1 (mg:mg) dosing reference. Source not verified; entry left unlinked.
MHRA marketing-authorisation status of cagrisema (none as of 2026). UK regulatory resource; entry left unlinked.
MHRA status, cagrilintide half-life and amylin mechanism reference. Source not verified; entry left unlinked.
Ozempic/Wegovy (semaglutide) Summary of Product Characteristics — missed-dose and storage guidance. Source not verified; entry left unlinked.
Semaglutide half-life and cagrisema investigational-status reference. Source not verified; entry left unlinked.
Cagrisema investigational (non-MHRA-authorised) status as of 2026. UK regulatory resource; entry left unlinked.
Cagrisema research-use / investigational phase 3 status disclaimer. UK regulatory resource; entry left unlinked.
Cagrisema research-use / investigational phase 3 status disclaimer. UK regulatory resource; entry left unlinked.

All Body Pharm products are sold strictly for research and analytical purposes only. Not for human consumption.